Skip to content

Sciensus is proud to sponsor the World Orphan Drug Congress USA 2026, the leading global forum bringing together rare disease innovators, regulators and patient advocacy groups to advance access for orphan and ultra-rare therapies.

As rare disease pipelines grow more complex, access delays across Europe continue to challenge US biotechs. From regulatory strategy and early access through to evidence generation and sustainable commercial delivery, Sciensus supports biopharma companies at every stage of the journey.

Meet the Sciensus team at the WODC USA 2026

Christian Tucat

Chief Executive Officer

Julie Gosper

Managing Director, Rare & Specialty

Jeremy Mangelson

SVP, Business Development North America & APAC

Mandi Walters

SVP, Business Development North America

Your integrated commercialisation partner for Europe

Are you navigating the complexities of launching a rare or orphan therapy in Europe?

At WODC USA 2026, discover how Sciensus helps biotechs accelerate patient access, generate early real world evidence and unlock long term value through an integrated European commercialisation model.

Speak with our team and learn how we support:

  • Faster routes to patient access across the EU and UK
  • Early evidence generation to support reimbursement and pricing decisions
  • Sustainable commercial success beyond traditional out licensing models

Expertise that makes the difference

Leveraging over 30 years of clinical experience, deep therapeutic expertise and personalised digital innovation, we help biopharma, CROs and CCOs bring treatments to patients across Europe faster.

$ 380,000,000 +

orphan drugs bought and sold per year

0

relationships with healthcare providers

0 +

units of orphan medicine supplied

 

Get a faster route into Europe

Request a meeting for a focused strategic conversation on your asset, where we’ll explore how you can accelerate access to Europe by using one integrated partner for end-to-end support.

This field is for validation purposes and should be left unchanged.